Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis.

Simón Serrano S, Grönberg A, Longato L, Rombouts K, Kuo J, Gregory M, Moss S, Elmér E, Mazza G, Gallay P, Pinzani M, Hansson MJ, Massoumi R.

Cells. 2019 Nov 8;8(11). pii: E1409. doi: 10.3390/cells8111409.

2.

Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis.

Kuo J, Serrano SS, Grönberg A, Massoumi R, Hansson MJ, Gallay P.

Front Pharmacol. 2019 Sep 26;10:1129. doi: 10.3389/fphar.2019.01129. eCollection 2019.

3.

A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Kuo J, Bobardt M, Chatterji U, Mayo PR, Trepanier DJ, Foster RT, Gallay P, Ure DR.

J Pharmacol Exp Ther. 2019 Nov;371(2):231-241. doi: 10.1124/jpet.119.261099. Epub 2019 Aug 12.

4.

The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate.

Bobardt M, Kuo J, Chatterji U, Chanda S, Little SJ, Wiedemann N, Vuagniaux G, Gallay PA.

PLoS One. 2019 Feb 4;14(2):e0211746. doi: 10.1371/journal.pone.0211746. eCollection 2019.

5.

yylncT Defines a Class of Divergently Transcribed lncRNAs and Safeguards the T-mediated Mesodermal Commitment of Human PSCs.

Frank S, Ahuja G, Bartsch D, Russ N, Yao W, Kuo JC, Derks JP, Akhade VS, Kargapolova Y, Georgomanolis T, Messling JE, Gramm M, Brant L, Rehimi R, Vargas NE, Kuroczik A, Yang TP, Sahito RGA, Franzen J, Hescheler J, Sachinidis A, Peifer M, Rada-Iglesias A, Kanduri M, Costa IG, Kanduri C, Papantonis A, Kurian L.

Cell Stem Cell. 2019 Feb 7;24(2):318-327.e8. doi: 10.1016/j.stem.2018.11.005. Epub 2018 Dec 13.

PMID:
30554961
7.

Prognostic value of tumor volume for patients with advanced lung cancer treated with chemotherapy.

Kuo CJ, Ke BH, Wu NY, Kuo J, Hsu HH.

Comput Methods Programs Biomed. 2017 Jun;144:165-177. doi: 10.1016/j.cmpb.2017.03.021. Epub 2017 Mar 30.

PMID:
28495000
8.

Borrelia-primed and -infected mice deficient of interleukin-17 develop arthritis after neutralization of gamma-interferon.

Kuo J, Warner TF, Schell RF.

Pathog Dis. 2017 Mar 1;75(2). doi: 10.1093/femspd/ftx014.

PMID:
28175297
9.

Automatic and quantitative measurement of laryngeal video stroboscopic images.

Kuo CJ, Kuo J, Hsiao SW, Lee CL, Lee JC, Ke BH.

Proc Inst Mech Eng H. 2017 Jan;231(1):48-57. doi: 10.1177/0954411916679200. Epub 2016 Dec 21.

PMID:
28097934
10.

Arthritis is developed in Borrelia-primed and -infected mice deficient of interleukin-17.

Kuo J, Warner TF, Munson EL, Nardelli DT, Schell RF.

Pathog Dis. 2016 Oct;74(7). pii: ftw077. doi: 10.1093/femspd/ftw077. Epub 2016 Aug 4.

PMID:
27493062
11.

Interleukin-10 (IL-10) inhibits Borrelia burgdorferi-induced IL-17 production and attenuates IL-17-mediated Lyme arthritis.

Hansen ES, Medić V, Kuo J, Warner TF, Schell RF, Nardelli DT.

Infect Immun. 2013 Dec;81(12):4421-30. doi: 10.1128/IAI.01129-13. Epub 2013 Sep 16.

12.

Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice.

Kuo J, Nardelli DT, Warner TF, Callister SM, Schell RF.

Clin Vaccine Immunol. 2011 Jul;18(7):1125-32. doi: 10.1128/CVI.00052-11. Epub 2011 May 25.

13.

Characterization of a temperature-sensitive vertebrate clathrin heavy chain mutant as a tool to study clathrin-dependent events in vivo.

Neumann-Staubitz P, Hall SL, Kuo J, Jackson AP.

PLoS One. 2010 Aug 6;5(8):e12017. doi: 10.1371/journal.pone.0012017.

14.

Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient.

Kuo J, Hwu HG.

Clin Neuropharmacol. 2008 May-Jun;31(3):173-5. doi: 10.1097/WNF.0b013e318123ee01.

PMID:
18520984

Supplemental Content

Loading ...
Support Center